Target Name: TESC
NCBI ID: G54997
Review Report on TESC Target / Biomarker Content of Review Report on TESC Target / Biomarker
TESC
Other Name(s): Tescalcin, transcript variant 1 | Calcineurin B homologous protein 3 (isoform 1) | TESC variant 1 | Tescalcin | CHP3 | OTTHUMP00000185561 | Calcineurin B homologous protein 3 | TSC | tescalcin | calcineurin-like EF hand protein 3 | FLJ20607 | CHP3_HUMAN

Tescalcin: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

TESC (Tescalcin, transcript variant 1) is a drug target and a biomarker that is currently being studied for its potential uses in treating various diseases. Tescalcin is a small molecule inhibitor of protein kinase C (PKC), which is a protein that is involved in many cellular processes in the body. PKC is known to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and development of Tescalcin

Tescalcin was first discovered in the early 1990s by a research team at the University of California, San Diego. The team identified a protein called PKC as a potential drug target and began researching ways to inhibit its activity. They found that Tescalcin, a naturally occurring compound in the soil, was able to inhibit the activity of PKC and was able to cause a regression of cancer cells in cell experiments.

Subsequent studies have shown that Tescalcin is effective in inhibiting the activity of PKC in a variety of cell types and in animal models of disease. It has been shown to be particularly effective in inhibiting the activity of PKC in cancer cells, which makes it a promising drug target for cancer treatment.

The potential uses of Tescalcin

Tescalcin has a variety of potential uses in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer treatment, Tescalcin has been shown to be effective in inhibiting the growth and spread of cancer cells. It has also been shown to cause a regression of tumors in animal models of cancer. These results are encouraging and suggest that Tescalcin may be an effective cancer treatment.

In neurodegenerative diseases, Tescalcin has been shown to protect against neurodegeneration and to cause regression of neurodegenerative diseases in animal models. This suggests that Tescalcin may be an effective treatment for neurodegenerative diseases.

In autoimmune disorders, Tescalcin has been shown to reduce the activity of immune cells and to cause regression of autoimmune disorders in animal models. This suggests that Tescalcin may be an effective treatment for autoimmune disorders.

The safety and effectiveness of Tescalcin have not been fully evaluated in human clinical trials. However, the results of the animal studies are promising and suggest that Tescalcin may be an effective and safe drug.

The future of Tescalcin

Tescalcin is currently being studied in a variety of clinical trials to determine its safety and effectiveness as a cancer, neurodegenerative disease, and autoimmune disorder treatment.

In cancer treatment, Tescalcin is being studied in a randomized, double-blind, placebo-controlled trial to determine its effectiveness in inhibiting the growth and spread of cancer cells. The results of this trial are currently being sought.

In neurodegenerative diseases, Tescalcin is being studied in a variety of preclinical models to determine its effectiveness in protecting against neurodegeneration and in causing regression of neurodegenerative diseases. The results of these studies are promising and suggest that Tescalcin may be an effective treatment for neurodegenerative diseases.

In autoimmune disorders, Tescalcin is being studied in a preclinical model to determine its effectiveness in reducing the activity of immune cells and in causing regression of autoimmune disorders. The results of these studies are promising and suggest that Tescalcin may be an effective treatment for autoimmune disorders.

Conclusion

Tescalcin is a drug target and a biomarker that is being studied for its potential uses in treating various diseases. The results of the animal studies are promising and suggest that Tescalcin may be an effective and safe drug. Further studies are needed to evaluate its safety and effectiveness in human clinical trials.

Protein Name: Tescalcin

Functions: Functions as an integral cofactor in cell pH regulation by controlling plasma membrane-type Na(+)/H(+) exchange activity. Promotes the maturation, transport, cell surface stability and exchange activity of SLC9A1/NHE1 at the plasma membrane. Promotes the induction of hematopoietic stem cell differentiation toward megakaryocytic lineage. Essential for the coupling of ERK cascade activation with the expression of ETS family genes in megakaryocytic differentiation. Also involved in granulocytic differentiation in a ERK-dependent manner. Inhibits the phosphatase activity of calcineurin

The "TESC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TESC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2 | TGFBR3 | TGFBR3L | TGFBRAP1 | TGIF1 | TGIF2